Burjeel Holdings, a leading healthcare provider in the UAE, has partnered with Paige, a US-based leader in AI for cancer diagnostics. This partnership aims to improve access to advanced cancer pathology services across the MENA region, particularly in underserved areas.
Addressing Pathologist Shortages and Improving Diagnostic Speed
Through this partnership, Burjeel Holdings will implement Paige’s AI-powered pathology tools across its network. These tools will speed up cancer diagnoses, increase accuracy, and help doctors make better treatment decisions.
The collaboration also tackles the global shortage of pathologists. By using AI, the partnership ensures more consistent and accurate diagnoses, even in regions with limited medical resources.
“Integrating AI into our pathology services will speed up and improve the accuracy of cancer diagnoses, leading to better treatment outcomes,” said John Sunil, CEO of Burjeel Holdings. “This also aligns with our goal to bring world-class care to emerging markets.”
Making AI Cancer Diagnostics Accessible Worldwide
Peter Hamilton, General Manager of Diagnostics at Paige, said: “Burjeel Holdings’ focus on innovation and equitable care makes them an ideal partner in closing diagnostic gaps and expanding access to AI-powered cancer diagnostics.”
The partnership supports Paige’s global mission to make advanced diagnostic tools widely available. Paige has received FDA Breakthrough Device Designation for its key AI solutions, including Paige PanCancer Detect, Paige Breast Lymph Node, and Paige Prostate Detect.
Burjeel will also use Paige OmniScreen, which screens over 1,600 molecular biomarkers. This tool enables more thorough cancer diagnoses and helps doctors personalize treatment plans for patients.
